Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Capstan Therapeutics to Participate in Upcoming Investor Conferences By: Capstan Therapeutics, Inc. via Business Wire September 25, 2024 at 07:30 AM EDT Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will participate in the following investor conferences: Goldman Sachs Cell Therapy Day 2024 Date: Tuesday, October 1, 2024 Location: New York, NY Chief Medical Officer, Ramin Farzaneh-Far, M.D., will participate in a panel discussion focused on innovations in cell therapies. Leerink Partners Biopharma Private Company Connect Date: Tuesday, October 22 and Wednesday, October 23, 2024 Location: Virtual Capstan management will participate in virtual 1x1 investor meetings. About Capstan Therapeutics, Inc. (www.capstantx.com) Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter). View source version on businesswire.com: https://www.businesswire.com/news/home/20240925333730/en/Contacts Investors: Miguel Arcinas Senior Vice President of Corporate Development Capstan Therapeutics marcinas@capstantx.com Media: Rhiannon Jeselonis Ten Bridge Communications rhiannon@tenbridgecommunications.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Capstan Therapeutics to Participate in Upcoming Investor Conferences By: Capstan Therapeutics, Inc. via Business Wire September 25, 2024 at 07:30 AM EDT Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will participate in the following investor conferences: Goldman Sachs Cell Therapy Day 2024 Date: Tuesday, October 1, 2024 Location: New York, NY Chief Medical Officer, Ramin Farzaneh-Far, M.D., will participate in a panel discussion focused on innovations in cell therapies. Leerink Partners Biopharma Private Company Connect Date: Tuesday, October 22 and Wednesday, October 23, 2024 Location: Virtual Capstan management will participate in virtual 1x1 investor meetings. About Capstan Therapeutics, Inc. (www.capstantx.com) Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter). View source version on businesswire.com: https://www.businesswire.com/news/home/20240925333730/en/Contacts Investors: Miguel Arcinas Senior Vice President of Corporate Development Capstan Therapeutics marcinas@capstantx.com Media: Rhiannon Jeselonis Ten Bridge Communications rhiannon@tenbridgecommunications.com
Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will participate in the following investor conferences: Goldman Sachs Cell Therapy Day 2024 Date: Tuesday, October 1, 2024 Location: New York, NY Chief Medical Officer, Ramin Farzaneh-Far, M.D., will participate in a panel discussion focused on innovations in cell therapies. Leerink Partners Biopharma Private Company Connect Date: Tuesday, October 22 and Wednesday, October 23, 2024 Location: Virtual Capstan management will participate in virtual 1x1 investor meetings. About Capstan Therapeutics, Inc. (www.capstantx.com) Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter). View source version on businesswire.com: https://www.businesswire.com/news/home/20240925333730/en/
Investors: Miguel Arcinas Senior Vice President of Corporate Development Capstan Therapeutics marcinas@capstantx.com Media: Rhiannon Jeselonis Ten Bridge Communications rhiannon@tenbridgecommunications.com